Ab stract Owing to recent findings of certain unusual sex steroid binding in liver disease particularly an allosteric biphasic pattern (pattern A) unique to the serum of patients' with hepatocellular carcinoma-the serum binding characteristics for 5a-dihydrotestosterone were examined in serum samples from six patients with primary biliary cirrhosis who had developed hepatocellular carcinoma. In all serum samples taken after the development of tumour pattern A binding only was obtained, and in four cases in which earlier samples were also examined there was a transformation from the normal, non-specific binding pattern, or an allosteric plateau pattern seen in non-malignant liver disease (designated D and C respectively), to pattern A coincident with the rise in serum x fetoprotein. In one patient chemotherapy leading to a fall in x fetoprotein abolished pattern A binding, showing further its close association with tumour growth. The value of pattern A binding as a tumour marker in hepatocellular carcinoma warrants further study. Introduction Studies using the two tier column assay' for binding of sex steroids in serum have detected two novel patterns of binding in the Cibacron blue 3GA-Sepharose 6B (blue gel) portion of the colunm when sera from patients with liver disease were examined. The first-a biphasic allosteric pattern (pattern A)-was found only in sera from patients with hepatocellular carcinoma and in fetal liver cytosol,' 3 and the second-an allosteric plateau pattern (pattern C)-was found in non-malignant liver disease, including primary biliary cirrhosis.3 Both patterns were attributed to a single binding moiety, termed fetal steroid binding protein. These two binding patterns are distinct from the more usual form of sex steroid binding associated with high affinity, low capacity specific binding protein such as sex hormone binding globulin, androgen, and oestrogen receptors (pattern B) and the low affinity, high capacity non-specific binding to proteins such as human serum albumin (pattern D).
We have examined serum samples from six patients with primary biliary cirrhosis in whom hepatocellular carcinoma had developed. The novel sex steroid binding patterns were investigated in relation to time of diagnosis and changes in serum x fetoprotein concentrations.
Patients and methods
Of 130 patients (18 men) with primary biliary cirrhosis seen in the liver unit during 1975-83, seven were found to have developed hepatocellular carcinoma six months to nine years after diagnosis of the cirrhosis.4 Hepatocellular carcinoma was confirmed histologically and in six patients serum samples were available, which are the subject of this study (table) . Serial samples were available in five patients, in four of whom at least one sample antedated the rise in serum a fetoprotein concentration.
The two tier column assay was carried out as described' on serum samples diluted 1/5 in trometamol (TRIS) buffer (0 05M trometamol, 0-005M calcium chloride pH 7-5) and incubated with a range of radioinert 57-androstan-17ox-ol,3-one (DHT) concentrations (0-172 nmol) and a constant amount of 3H-DHT. Binding in the Cibacron blue 3GA-Sepharose 6B (blue gel) fractions and in the column eluates was determined and the data analysed by plots of percentage binding. Serum x fetoprotein concentrations were determined by radioimmunoassay (Amersham International), the upper limit of normal being taken as 10 jg/l.
Results
Serum from the time of diagnosis of hepatocellular carcinoma onwards showed the typical biphasic allosteric pattern (pattern A) of sex steroid binding in all six patients. This was not present in the pretumour samples available in four of the cases, three displaying pattern C and one non-specific (pattern D) binding characteristics. In samples obtained from two patients (cases 4 and 6) when a fetoprotein concentrations were just beginning to rise (9 5 and 30 0 mg/l respectively) pattern D binding was seen. Subsequent samples in both patients (obtained when there had been a steep rise in a fetoprotein concentrations three and six months respectively from the time of the first slight increase) showed pattern A binding (figure). When the serum x fetoprotein concentration fell in case 1 after cytotoxic drug treatment the pattern A binding reverted to the non-specific (pattern D) binding. In none of the other patients did a fall in serum x fetoprotein or loss of the pattern A binding take place.
Serum concentrations of sex hormone binding globulin were raised in all patients at the time of diagnosis of hepatocellular carcinoma but there were no significant differences from the values found in the patients before development of tumour.
Discussion
The patterns A and C described here differ from the widely known patterns of sex steroid binding to high affinity, low capacity binding proteins such as sex hormone binding globulin (pattern B) or low affinity, high capacity binding proteins such as human serum albumin (pattern D) and are not amenable to the usual forms of graphical analysis applied to binding proteins. The presence of pattern A binding of fetal steroid binding protein at the time of diagnosis in all six patients and its close correlation with a fetoprotein concentrations in both appearance and disappearance, point to its specificity as a marker of hepatocellular carcinoma. The presence of the non-specific binding pattern (pattern D) at the onset of the increase in a fetoprotein in two cases suggests a transition in the binding characteristics of fetal steroid binding protein before pattern A is expressed ( figure) . Human x fetoprotein does not bind oestrogens or androgens,5 and pattern A has been found in two patients with no increase in serum a fetoprotein,3 while in liver cytosol from a patient with hepatoblastoma and a serum concentration of 658 000 F±g/l no specific sex steroid binding could be detected.6 x Fetoprotein may therefore be ruled out as the cause of specific blue gel binding.
Our results further confirm other studies on the specificity of this binding pattern, which was exhibited by 20 of 23 samples from patients with hepatocellular carcinoma but not in a large control group comprising patients with cirrhosis, patients with carcinoma of the breast and prostate, and normal subjects.3 Fetal steroid binding protein from fetal liver cytosol was shown to have a molecular weight of 52 000 daltons and an Rf value on polyacrylamide gel electrophoresis of 0-48 and to precipitate in 2-025M ammonium sulphate.2 The circulating protein(s) displayed similar characteristics but were also glycoproteins, as shown by their immobilisation on concanavalin A Sepharose 4B.3 Fetal steroid binding protein from all sources bound DHT more strongly than testosterone and both androgens more strongly than oestradiol-17P.' Patterns A and C binding are not due to a single set of equivalent and homogeneous binding sites but are due to a more complex interaction of binding proteins, which makes determination of binding parameters not possible at present. Hence the development of a quantitative assay is desirable. Using graphical representation as a guide, however, we have found no "false positive" cases in over 200 serum samples, including 77 from patients with liver disease and 43 from patients with malignancies associated with sex steroid hormones. Primary biliary cirrhosis is rarely complicated by hepatocellular carcinoma7 and the cases reported here were not suspected clinically, two being detected only at necropsy and four by rises in the serum x fetoprotein concentration. Therefore, the finding of pattern A in two patients with the tumour who had no rise in serum x fetoprotein3 is of potential clinical importance. A raised x fetoprotein concentration is found in 850 of patients with hepatocellular carcinoma as a complication of cirrhosis but in only half of those without underlying liver disease8; the value of pattern A binding as a tumour marker in hepatocellular carcinoma therefore merits further investigation.
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